RISK PROFILE AND ANTIHYPERTENSIVE TREATMENT EFFICACY IN PATIENTS REFERRED TO THE CARDIOLOGICAL CENTRE: POST-HOC ANALYSIS

Background: Arterial hypertension (HTN) remains a key risk factor for cardiovascular disease burden and mortality. Efficacy of treatment differs across regions, depending on various medical facilities. Assessment of specific features of antihypertensive treatment (AHT) provided in cardiology outpatient care setting is of special interest.

Objective: To investigate comorbidity and cardiovascular risk factors and to determine the features of treatment in patients with HTN referred to federal cardiology center.

Design and methods: Retrospective analysis was conducted using 100 randomly selected electronic health records of patients who had attended to the Almazov National Medical Research Centre (former Federal Almazov North-West Medical Research Centre) seeking for doctor’s advice on cardiovascular diseases in the period from 2010-2013. Men (n=44) and women (n=56) aged 23 to 88 years (59 ± 13 years) represented a sample size. HTN was diagnosed as systolic blood pressure (SBP) ≥140 mmHg, diastolic blood pressure (DBP) ≥90 mmHg, or if patient had been receiving antihypertensive therapy. The efficacy of treatment was taken as target BP achievement by patients on AHT. Controlled hypertension shall mean the number of patients reached target BP levels among all hypertensives. AHT was analyzed with defining its type and groups of prescribed medications.

Results: In vast majority of cases HTN was associated with overt cardiovascular diseases. An incidence of tobacco smoking was minimal while obesity and diabetes mellitus were diagnosed typically in patients with HTN. Mean SBP and DBP levels were 143±23 mmHg and 87±11 mmHg, respectively. Antihypertensive treatment was prescribed for all hypertensive patients (n=82), 62% of them were taking medications (n = 51), while women were more adherent to doctors’ advices (p = 0.026). Effective treatment was observed in (n=40) 78% of cases, and in 65% (n = 53) of them HTN was controlled. Most patients were prescribed combination therapy (n = 65) 79%, more often – a threedrug combination (n=32, 48.5%). Antihypertensive drugs were mainly beta-adrenoblockers, ACE inhibitors and diuretics.

Conclusion: There is a strict association of HTN with overt cardiovascular diseases. More than half of the patients achieved adequate blood pressure control. Young female patients who take combination therapy regularly and those with concomitant chronic heart failure are likely to have HTN to be under control.

1. Go AS, Mozaffarian D, Roger VL et al. Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127: 143– 152.

2. Lim SS, Vos T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2224–2260.

3. Ford ES, Véronique LR, Shannon MD et al. Challenges of Ascertaining National Trends in the Incidence of Coronary Heart Disease in the United States. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2014; 3(6): 1-22.

4. Ettehad D, Connor AE, Amit K et al. Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: A Systematic Review and Meta-Analysis. Lancet. 2015; 387(122): 957–967.

5. Tao L, Cunying P, Shutong S et al. Tendency for Age-Specific Mortality with Hypertension in the European Union from 1980 to 2011. International Journal of Clinical and Experimental Medicine. 2015; 8(2): 1611–1623.

6. Mosca I, Rose AK. Exploring Differences in Prevalence of Diagnosed, Measured and Undiagnosed Hypertension: The Case of Ireland and the United States of America. International Journal of Public Health. 2014; 59(5): 759–767.

7. ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal. 2013; 34: 2159–2219.

8. Padwal RS, Asako B, Finlay AM et al. Epidemiology of Hypertension in Canada: An Update. The Canadian Journal of Cardiology. 2012; 32(5): 687–694.

9. Redon J, Jean-Jacques M, Roland E et al. Why in 2016 Are Patients with Hypertension Not 100% Controlled? A Call to Action. Journal of Hypertension. 2016; 34(8): 1480–1488.

10. Yoon SSS, Margaret DC, Cheryl DF. Hypertension Prevalence and Control Among Adults: United States, 2011-2014. NCHS Data Brief. 2015; 220: 1–8.

11. Chazova IE, Zhernakova YuV, Oshchepkova EV et al. Prevalence of Cardiovascular Risk Factors in Russian Population of Patients With Arterial Hypertension. Kardiologiia. 2014: 54(10): 4–12. In Russian [Чазова И. Е., Жернакова Ю. В., Ощепкова Е. В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 54(10): 4–12].

12. Boytsov SA, Balanova YA, Shalnova SA et al. Arterial Hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014; 13(4): 4-14. In Russian [Бойцов С. А., Баланова Ю. А., Шальнова С. А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2015; 13(4): 4–14].

13. Sinkova GM Epidemiology of Arterial Hypertension, Syberian medical journal. 2007; 8: 5-10. In Russian [Синькова Г.М. Эпидемиология артериальной гипертензии. Сибирский медицинский журнал, 2007; 8: 5-10].

14. Shapovalova AB. The Rate of Arterial Hypertension and Other Components of Metabolic Syndrome According to Analysis of Out-Patient Documention. National Scientist’s Association. 2015; 7 (12): 167-169. In Russian [Шаповалова А.Б. Частота артериальной гипертензии и других компонентов метаболического синдрома по данным анализа медицинских карт амбулаторного больного. Национальная Ассоциация Ученых. 2015; 7 (12): 167–169].

15. Lavrienko AV. Gender-sensitive development of cardiovascular diseases. Bulletin of Medical Online Conferences. 2016; 6(5): 451. In Russian [Лавриенко А.В. Гендерные особенности развития сердечно-сосудистых заболеваний. Бюллетень Медицинских Интернет-Конференций. 2016; 6(5): 451].

16. Orlov AV, Rotar OP, Boyarinova MA et al. Gender Differences of Behavioral Risk Factors in Saint-Petersburg Inhabitants. Annals of the Russian academy of medical sciences. 2015; 70(5): 585-591. In Russian [Орлов А. В., Ротарь О. П., Бояринова М. А. и др. Гендерные особенности распространенности поведенческих факторов риска у жителей Санкт-Петербурга. Вестник Российской академии медицинских наук 2015; 70(5): 585–591].

17. Kettani FZ, Dragomir A, Robert C et al. Impact of a Better Adherence to Antihypertensive Agents on Cerebrovascular Disease for Primary Prevention. Stroke. 2009; 40(1): 213–220.

18. Perreault S, Dragomir A, White M et al. Better Adherence to Antihypertensive Agents and Risk Reduction of Chronic Heart Failure. Journal of Internal Medicine. 2009; 266(2): 207–218.

19. Perreault S, Dragomir A, Louise R et al. Adherence Level of Antihypertensive Agents in Coronary Artery Disease. British Journal of Clinical Pharmacology. 2010; 69(1): 74–84.

20. World Health Organisation: Adherence to long-term therapies, evidence for action. http://apps.who.int/iris/bitstream/10665/42682/1/9241545992.pdf (Mar 03, 2017).

21. Shalnova SA, Deev AD, Balanova YA et al. Treatment of hypertension in high-risk patients. Monotherapy or combination? Lechaschii Vrach Journal. 2016; 7: 17-23. In Russian [Шальнова С. А., Деев А. Д., Баланова Ю. А. и др. Лечение гипертонии у пациентов высокого риска. Монотерапия или комбинация? Лечащий Врач. 2016; 7: 17-23].

22. Leonetti G, Egan CG. Use of carvedilol in hypertension: an update. Vascular Health and Risk Management. 2012; 8: 307–322.

23. Fongemie J, Felix-Getzik E. A Review of Nebivolol Pharmacology and Clinical Evidence. Drugs. 2015; 75(12): 1349–1371.

24. Larochelle P, Tobe SW, Lacourcière Y. β-Blockers in hypertension: studies and meta-analyses over the years. Canadian Journal of Cardiology. 2014; 30(5): S16-22.

25. DiNicolantonio JJ, Hassan F, Asfandyar KN et al. β-Blockers in Hypertension, Diabetes, Heart Failure and Acute Myocardial Infarction: A Review of the Literature. Open Heart. 2015; 2(1): e000230.

26. Kubon C, Mistry NB, Grundvold I et al. The role of beta-blockers in the treatment of chronic heart failure. Trends in Pharmacological Sciences. 2011; 32(4): 206-212.

27. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 2016 ;18(8): 891-975.

28. Konishi H, Miyauchi K, Kasai T et al. Long-term effect of β-blocker in ST-segment elevation myocardial infarction in patients with preserved left ventricular systolic function: a propensity analysis. Heart and Vessels. 2016 ;31(4): 441-448.